Nigrostriatal denervation changes the effect of cannabinoids on subthalamic neuronal activity in rats

Psychopharmacology

Volumn 214, Issue 2, 2011, Pages 379-389

  Morera Herreras, Teresa ^a   Ruiz Ortega, José Ángel ^a   Linazasoro, Gurutz ^b   Ugedo, Luisa ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b Centro de Investigacion Parkinson   (Spain)

Author keywords

6 Hydroxydopamine; Basal ganglia; Cannabinoid; Electrophysiology; Parkinson's disease

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; RIMONABANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; DENERVATION; DOPAMINERGIC NERVE CELL; DRUG ACTIVITY; ELECTRIC ACTIVITY; MALE; NERVE CELL STIMULATION; NEUROPHYSIOLOGY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT; SUBTHALAMIC NUCLEUS;

ACTION POTENTIALS; ANALYSIS OF VARIANCE; ANIMALS; ARACHIDONIC ACIDS; BASAL GANGLIA; BENZOXAZINES; CANNABINOIDS; CHI-SQUARE DISTRIBUTION; DENERVATION; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS; INJECTIONS, INTRAVENTRICULAR; MALE; MORPHOLINES; NAPHTHALENES; NEURAL INHIBITION; NEURONS; OXIDOPAMINE; POLYUNSATURATED ALKAMIDES; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; TETRAHYDROCANNABINOL;

EID: 79952282657     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-2043-0     Document Type: Article

References (66)

1. GE Alexander MD Crutcher 1990 Functional architecture of basal ganglia circuits: neural substrates of parallel processing Trends Neurosci 13 266 271 1695401 10.1016/0166-2236(90)90107-L 1:CAS:528:DyaK3MXjs1Snuw%3D%3D (Pubitemid 20193456)
2. A Benazzouz B Piallat ZG Ni A Koudsie P Pollak AL Benabid 2000 Implication of the subthalamic nucleus in the pathophysiology and pathogenesis of Parkinson's disease Cell Transplant 9 215 221 10811394 1:STN:280: DC%2BD3czosVOmsA%3D%3D (Pubitemid 30252687)
3. H Bergman T Wichmann B Karmon MR DeLong 1994 The primate subthalamic nucleus II Neuronal activity in the MPTP model of Parkinsonism J Neurophysiol 72 507 520 7983515 1:STN:280:DyaK2M%2FnsVKmuw%3D%3D (Pubitemid 24273560)
4. H Bergman A Feingold A Nini A Raz H Slovin 1998 Physiological aspects of information processing in the basal ganglia of normal and Parkinsonian primates Trends Neurosci 21 32 38 9464684 10.1016/S0166-2236(97)01151-X 1:CAS:528:DyaK1cXhtlGgtQ%3D%3D (Pubitemid 128766376)
5. G Bilbao JA Ruiz-Ortega N Miguens I Ulibarri G Linazasoro S Gomez-Urquijo J Garibi L Ugedo 2006 Electrophysiological characterization of substantia nigra dopaminergic neurons in partially lesioned rats: effects of subthalamotomy and levodopa treatment Brain Res 1084 175 184 16574080 10.1016/j.brainres.2006.02. 052 1:CAS:528:DC%2BD28Xks1WltL4%3D
6. T Bisogno F Berrendero G Ambrosino M Cebeira JA Ramos JJ Fernandez-Ruiz V Di Marzo 1999 Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function Biochem Biophys Res Commun 256 377 380 10079192 10.1006/bbrc.1999.0254 1:CAS:528:DyaK1MXhvVaiur4%3D (Pubitemid 29298893)
7. F Blandini G Nappi C Tassorelli E Martignoni 2000 Functional changes of the basal ganglia circuitry in Parkinson's disease Prog Neurobiol 62 63 88 10821982 10.1016/S0301-0082(99)00067-2 1:CAS:528:DC%2BD3cXltFWnurs%3D (Pubitemid 30252017)
8. S Breit R Bouali-Benazzouz RC Popa T Gasser AL Benabid A Benazzouz 2007 Effects of 6-hydroxydopamine-induced severe or partial lesion of the nigrostriatal pathway on the neuronal activity of pallido-subthalamic network in the rat Exp Neurol 205 36 47 17395181 10.1016/j.expneurol.2006.12.016 1:CAS:528:DC%2BD2sXkslOhs7w%3D (Pubitemid 46617488)
9. JM Brotchie 2003 CB1 cannabinoid receptor signalling in Parkinson's disease Curr Opin Pharmacol 3 54 61 12550742 10.1016/S1471-4892(02)00011-5 1:CAS:528:DC%2BD3sXmsVaqsw%3D%3D (Pubitemid 36131327)
10. P Burbaud C Gross A Benazzouz M Coussemacq B Bioula 1995 Reduction of apomorphine-induced rotational behaviour by subthalamic lesion in 6-OHDA lesioned rats is associated with a normalization of firing rate and discharge pattern of pars reticulata neurons Exp Brain Res 105 48 58 7589317 10.1007/BF00242181 1:CAS:528:DyaK2MXnslShtrc%3D
11. CB Carroll PG Bain L Teare X Liu C Joint C Wroath SG Parkin P Fox D Wright J Hobart JP Zajicek 2004 Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study Neurology 12 1245 1250 (Pubitemid 39350025)
12. P Consroe 1998 Brain cannabinoid systems as targets for the therapy of neurological disorders Neurobiol Dis 5 534 551 9974182 10.1006/nbdi.1998.0220 1:CAS:528:DyaK1MXhtFSqsb8%3D (Pubitemid 29075849)
13. JN Crawley RL Corwin JK Robinson CC Felder WA Devane J Axelrod 1993 Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents Pharmacol Biochem Behav 46 967 972 7906042 10.1016/0091-3057(93)90230-Q 1:CAS:528:DyaK2cXltFWgtg%3D%3D
14. P Damier 2009 Drug-induced dyskinesias Curr Opin Neurol 22 394 399 19491677 10.1097/WCO.0b013e32832d9dc4 1:CAS:528:DC%2BD1MXotFCmtrs%3D
15. V Di Marzo A Fontana H Cadas S Schinelli G Cimino JC Schwartz D Piomelli 1994 Formation and inactivation of endogenous cannabinoid anandamide in central neurons Nature 372 686 691 7990962 10.1038/372686a0
16. V Di Marzo M Bifulco L De Petrocellis 2004 The endocannabinoid system and its therapeutic exploitation Nat Rev Drug Discov 3 771 784 15340387 10.1038/nrd1495 (Pubitemid 39242829)
17. F El-Banoua I Caraballo JA Flores B Galan-Rodriguez E Fernandez-Espejo 2004 Effects on turning of microinjections into basal ganglia of D(1) and D(2) dopamine receptors agonists and the cannabinoid CB(1) antagonist SR141716A in a rat Parkinson's model Neurobiol Dis 16 377 385 15193294 10.1016/j.nbd.2004.03. 002 1:CAS:528:DC%2BD2cXkvVegtrk%3D (Pubitemid 38757319)
18. E Fernandez-Espejo I Caraballo FR de Fonseca F El Banoua B Ferrer JA Flores B Galan-Rodriguez 2005 Cannabinoid CB1 antagonists possess anti-Parkinsonian efficacy only in rats with very severe nigral lesion in experimental Parkinsonism Neurobiol Dis 18 591 601 15755685 10.1016/j.nbd.2004. 10.015 1:CAS:528:DC%2BD2MXhvFynsb8%3D (Pubitemid 40332717)
19. SH Fox B Henry M Hill A Crossman J Brotchie 2002 Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease Mov Disord 17 1180 1187 12465055 10.1002/mds.10289 (Pubitemid 36041331)
20. JP Frankel A Hughes AJ Lees GM Stern 1990 Marijuana for parkinsonian tremor J Neurol Neurosurg Psychiatry 53 436 2351975 10.1136/jnnp.53.5.436 1:STN:280:DyaK3c3nvVCmug%3D%3D (Pubitemid 20173284)
21. E Fride R Mechoulam 1993 Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent Eur J Pharmacol 231 313 314 8384116 10.1016/0014-2999(93)90468-W 1:CAS:528:DyaK3sXhsVCgtbc%3D (Pubitemid 23050919)
22. K Fujimoto H Kita 1993 Response characteristics of subthalamic neurons to the stimulation of the sensorimotor cortex in the rat Brain Res 609 185 192 8508302 10.1016/0006-8993(93)90872-K 1:STN:280:DyaK3s3osVequg%3D%3D (Pubitemid 23136818)
23. G Gerdeman DM Lovinger 2001 CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum J Neurophysiol 85 468 471 11152748 1:CAS:528:DC%2BD3MXjsFSmtro%3D (Pubitemid 32062158)
24. Y Gilgun-Sherki E Melamed R Mechoulam D Offen 2003 The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats Pharmacol Toxicol 93 66 70 12899667 10.1034/j.1600-0773.2003.930202.x 1:CAS:528:DC%2BD3sXms1Wht7g%3D (Pubitemid 36981411)
25. S Gonzalez C Scorticati M Garcia-Arencibia R de Miguel JA Ramos J Fernandez-Ruiz 2006 Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease Brain Res 1073-1074 209 219 16412990 10.1016/j.brainres.2005.12.014
26. P Gubellini B Picconi M Bari N Battista P Calabresi D Centonze G Bernardi A Finazzi-Agro M Maccarrone 2002 Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission J Neurosci 22 6900 6907 12177188 1:CAS:528:DC%2BD38XmsF2gsrY%3D (Pubitemid 35379148)
27. N Hajos TF Freund 2002 Distinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition Chem Phys Lipids 121 73 82 12505692 10.1016/S0009-3084(02)00149-4 1:CAS:528:DC%2BD38Xpslans74%3D (Pubitemid 36044544)
28. C Hamani JA Saint-Cyr J Fraser M Kaplitt AM Lozano 2004 The subthalamic nucleus in the context of movement disorders Brain 127 4 20 14607789 10.1093/brain/awh029 (Pubitemid 38055342)
29. OK Hassani M Mouroux J Feger 1996 Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus Neuroscience 72 105 115 8730710 10.1016/0306-4522(95)00535-8 1:CAS:528:DyaK28XitFaks7Y%3D (Pubitemid 26092990)
30. M Herkenham AB Lynn BR de Costa EK Richfield 1991 Neuronal localization of cannabinoid receptors in the basal ganglia of the rat Brain Res 547 267 274 1909204 10.1016/0006-8993(91)90970-7 1:CAS:528:DyaK3MXkt1ais7g%3D
31. AF Hoffman CR Lupica 2000 Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus J Neurosci 20 2470 2479 10729327 1:CAS:528:DC%2BD3cXit1aqsrY%3D (Pubitemid 30220334)
32. AF Hoffman M Oz R Yang AH Lichtman CR Lupica 2007 Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation Learn Mem 14 63 74 17202425 10.1101/lm.439007 1:CAS:528:DC%2BD1cXms1Ortbw%3D (Pubitemid 46203568)
33. AG Hohmann M Herkenham 2000 Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study Synapse 37 71 80 10842353 10.1002/(SICI)1098-2396(200007)37: 1<71::AID-SYN8>3.0.CO;2-K 1:CAS:528:DC%2BD3cXjsl2ntLw%3D (Pubitemid 30366503)
34. JR Hollerman AA Grace 1992 Subthalamic nucleus cell firing in the 6-OHDA-treated rat: basal activity and response to haloperidol Brain Res 590 291 299 1422838 10.1016/0006-8993(92)91108-Q 1:CAS:528:DyaK38XmtVGksbo%3D
35. MD Julian AB Martin B Cuellar F Rodriguez De Fonseca M Navarro R Moratalla LM Garcia-Segura 2003 Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia Neuroscience 119 309 318 12763090 10.1016/S0306-4522(03)00070-8 1:CAS:528:DC%2BD3sXjvFWntLc%3D (Pubitemid 36577432)
36. Y Kaneoke JL Vitek 1996 Burst and oscillation as disparate neuronal properties J Neurosci Methods 68 211 223 8912194 10.1016/0165-0270(96)00081-7 1:STN:280:DyaK2s%2FmvFSjtA%3D%3D (Pubitemid 26345963)
37. AC Kreitzer RC Malenka 2007 Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models Nature 8 643 647 10.1038/nature05506 (Pubitemid 46232883)
38. I Lastres-Becker M Cebeira ML de Ceballos BY Zeng P Jenner JA Ramos JJ Fernandez-Ruiz 2001 Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets Eur J Neurosci 14 1827 1832 11860478 10.1046/j.0953-816x.2001.01812.x 1:STN:280:DC%2BD387jvVSgsA%3D%3D (Pubitemid 35463701)
39. R Levy WD Hutchison AM Lozano JO Dostrovsky 2000 High-frequency synchronization of neuronal activity in the subthalamic nucleus of Parkinsonian patients with limb tremor J Neurosci 20 7766 7775 11027240 1:CAS:528: DC%2BD3cXns1eitro%3D
40. P Limousin P Pollak A Benazzouz D Hoffmann E Broussolle JE Perret AL Benabid 1995 Bilateral subthalamic nucleus stimulation for severe Parkinson's disease Mov Disord 10 672 674 8552123 10.1002/mds.870100523 1:STN:280: DyaK28%2FmsVentg%3D%3D
41. M Maccarrone P Gubellini M Bari B Picconi N Battista D Centonze G Bernardi A Finazzi-Agro P Calabresi 2003 Levodopa treatment reverses endocannabinoid system abnormalities in experimental Parkinsonism J Neurochem 85 1018 1025 12716433 10.1046/j.1471-4159.2003.01759.x 1:CAS:528: DC%2BD3sXktVGhu7w%3D (Pubitemid 36578633)
42. K Mackie 2005 Distribution of cannabinoid receptors in the central and peripheral nervous system Handb Exp Pharmacol 168 299 325 16596779 10.1007/3-540-26573-2-10 1:CAS:528:DC%2BD2MXkvFeqsL0%3D
43. CM Magariños-Ascone R Figueiras-Mendez C Riva-Meana A Cordoba-Fernandez 2000 Subthalamic neuron activity related to tremor and movement in Parkinson's disease Eur J Neurosci 12 2597 2607 10947834 10.1046/j.1460-9568.2000.00127.x (Pubitemid 30497053)
44. PJ Magill JP Bolam MD Bevan 2001 Dopamine regulates the impact of the cerebral cortex on the subthalamic nucleus-globus pallidus network Neuroscience 106 313 330 11566503 10.1016/S0306-4522(01)00281-0 1:CAS:528: DC%2BD3MXmvVyjtbw%3D (Pubitemid 32889632)
45. N Maurice JM Deniau J Glowinski AM Thierry 1998 Relationships between the prefrontal cortex and the basal ganglia in the rat: physiology of the corticosubthalamic circuits J Neurosci 18 9539 9546 9801390 1:CAS:528: DyaK1cXnsVKnsL0%3D (Pubitemid 28512482)
46. V Mesnage JL Houeto AM Bonnet I Clavier I Arnulf F Cattelin G Le Fur P Damier ML Welter Y Agid 2004 Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease Clin Neuropharmacol 27 108 110 15190231 10.1097/00002826-200405000-00003 1:CAS:528:DC%2BD2cXkslKgtLw%3D (Pubitemid 38746008)
47. T Morera-Herreras JA Ruiz-Ortega L Ugedo 2010 Two opposite effects of delta(9)-tetrahydrocannabinol on subthalamic nucleus neuron activity: involvement of GABAergic and glutamatergic neurotransmission Synapse 64 20 29 19725112 10.1002/syn.20701 1:CAS:528:DC%2BD1MXhtlOrt7zK
48. T Morera-Herreras JA Ruiz-Ortega A Taupignon J Baufreton I Manuel R Rodriguez-Puertas L Ugedo 2010 Regulation of subthalamic neuron activity by endocannabinoids Synapse 64 682 698 20336631 10.1002/syn.20701 1:CAS:528:DC%2BC3cXosl2mtL4%3D
49. MG Morgese T Cassano V Cuomo A Giuffrida 2007 Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors Exp Neurol 208 110 119 17900568 10.1016/j.expneurol.2007.07.021 1:CAS:528:DC%2BD2sXht1anurvK (Pubitemid 47600153)
50. ZG Ni R Bouali-Benazzouz DM Gao AL Benabid A Benazzouz 2001 Time-course of changes in firing rates and firing patterns of subthalamic nucleus neuronal activity after 6-OHDA-induced dopamine depletion in rats Brain Res 899 142 147 11311875 10.1016/S0006-8993(01)02219-3 1:CAS:528:DC%2BD3MXislGktb0%3D (Pubitemid 32324155)
51. P Pacher S Batkai G Kunos 2006 The endocannabinoid system as an emerging target of pharmacotherapy Pharmacol Rev 58 389 462 16968947 10.1124/pr.58.3.2 1:CAS:528:DC%2BD28XhtVOhtLfO (Pubitemid 44394908)
52. A Parent LN Hazrati 1995 Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop Brain Res Brain Res Rev 20 91 127 7711769 10.1016/0165-0173(94)00007-C 1:STN:280:DyaK2M3islaisA%3D%3D
53. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic, Orlando
54. 2 receptors Pharmacol Ther 72 129 180 10.1016/S0163-7258(97)82001-3 (Pubitemid 27337346)
55. B Piallat A Benazzouz AL Benabid 1999 Neuroprotective effect of chronic inactivation of the subthalamic nucleus in a rat model of Parkinson's disease J Neural Transm Suppl 55 71 77 10335494 1:STN:280:DyaK1M3msl2ktw%3D%3D (Pubitemid 29195798)
56. A Pisani F Fezza S Galati N Battista S Napolitano A Finazzi-Agro G Bernardi L Brusa M Pierantozzi P Stanzione M Maccarrone 2005 High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients Ann Neurol 57 777 779 15852389 10.1002/ana.20462 (Pubitemid 40628874)
57. J Romero F Berrendero A Perez-Rosado J Manzanares A Rojo JJ Fernandez-Ruiz JG de Yebenes JA Ramos 2000 Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen Life Sci 66 485 494 10794065 10.1016/S0024-3205(99)00618-9 1:CAS:528:DC%2BD3cXlsFKqug%3D%3D (Pubitemid 30062921)
58. J Romero I Lastres-Becker R de Miguel F Berrendero JA Ramos J Fernandez-Ruiz 2002 The endogenous cannabinoid system and the basal ganglia biochemical, pharmacological, and therapeutic aspects Pharmacol Ther 95 137 152 12182961 10.1016/S0163-7258(02)00253-X 1:CAS:528:DC%2BD38XmtlGqu7c%3D (Pubitemid 35232132)
59. MC Sañudo-Peña SL Patrick S Khen RL Patrick K Tsou JM Walker 1998 Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease Neurosci Lett 248 171 174 9654336 10.1016/S0304-3940(98)00368-1 (Pubitemid 28281382)
60. KA Sieradzan SH Fox M Hill JP Dick AR Crossman JM Brotchie 2001 Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study Neurology 11 2108 2111 (Pubitemid 33126882)
61. MA Silverdale S McGuire A McInnes AR Crossman JM Brotchie 2001 Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease Exp Neurol 169 400 406 11358453 10.1006/exnr.2001.7649 1:CAS:528:DC%2BD3MXjsF2lt7s%3D (Pubitemid 32524434)
62. PB Smith DR Compton SP Welch RK Razdan R Mechoulam BR Martin 1994 The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice J Pharmacol Exp Ther 270 219 227 8035318 (Pubitemid 24229631)
63. B Szabo I Wallmichrath P Mathonia C Pfreundtner 2000 Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulate Neuroscience 97 89 97 10771342 10.1016/S0306-4522(00)00036-1 1:CAS:528:DC%2BD3cXisFGhur4%3D (Pubitemid 30195879)
64. M Vila C Perier J Feger J Yelnik B Faucheux M Ruberg R Raisman-Vozari Y Agid EC Hirsch 2000 Evolution of changes in neuronal activity in the subthalamic nucleus of rats with unilateral lesion of the substantia nigra assessed by metabolic and electrophysiological measurements Eur J Neurosci 12 337 344 10651888 10.1046/j.1460-9568.2000.00901.x 1:STN:280:DC%2BD3c7hslGksg%3D%3D (Pubitemid 30068438)
65. I Wallmichrath B Szabo 2002 Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse Neuroscience 113 671 682 12150787 10.1016/S0306-4522(02)00109-4 1:CAS:528:DC%2BD38XlvVeltrY%3D (Pubitemid 34874691)
66. BY Zeng B Dass A Owen S Rose C Cannizzaro BC Tel P Jenner 1999 Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats Neurosci Lett 276 71 74 10624794 10.1016/S0304-3940(99)00762-4 1:CAS:528:DyaK1MXntlemur8%3D (Pubitemid 29525492)